These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 12064919)

  • 1. Expression of factor VIII in recombinant and transgenic systems.
    Soukharev S; Hammond D; Ananyeva NM; Anderson JA; Hauser CA; Pipe S; Saenko EL
    Blood Cells Mol Dis; 2002; 28(2):234-48. PubMed ID: 12064919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transgenic pigs produce functional human factor VIII in milk.
    Paleyanda RK; Velander WH; Lee TK; Scandella DH; Gwazdauskas FC; Knight JW; Hoyer LW; Drohan WN; Lubon H
    Nat Biotechnol; 1997 Oct; 15(10):971-5. PubMed ID: 9335047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant factor VIII: past, present and future of treatment of hemophilia A.
    Raso S; Hermans C
    Drugs Today (Barc); 2018 Apr; 54(4):269-281. PubMed ID: 29869648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological activity of a new recombinant human coagulation factor VIII and its efficacy in a small animal model.
    Wu J; Zhang H; Lian T; Ding Y; Song C; Li D; Wu L; Lei T; Liang H
    Biochem Biophys Res Commun; 2023 Jan; 640():80-87. PubMed ID: 36502635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives on progressive strategies and recent trends in the production of recombinant human factor VIII.
    Mannully ST; L N R; Pulicherla KK
    Int J Biol Macromol; 2018 Nov; 119():496-504. PubMed ID: 30063930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First and next generation native rFVIII in the treatment of hemophilia A. What has been achieved? Can patients be switched safely?
    Suiter TM
    Semin Thromb Hemost; 2002 Jun; 28(3):277-84. PubMed ID: 12098089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relevance of factor VIII (FVIII) pharmacokinetics to TDM and hemophilia a treatment: is B domain-deleted FVIII equivalent to full-length FVIII?
    Johnston A
    Ther Drug Monit; 2012 Feb; 34(1):110-7. PubMed ID: 22249347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics of the interaction between anti-FVIII antibodies and FVIII from therapeutic concentrates, with and without von Willebrand factor, assessed by surface plasmon resonance.
    Grancha S; Ortiz AM; Marañón C; Hampel K; Moret A; Zimmermann B; Jorquera JI; Aznar JA
    Haemophilia; 2012 Nov; 18(6):982-9. PubMed ID: 22646163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Confocal microscopy analysis of native, full length and B-domain deleted coagulation factor VIII trafficking in mammalian cells.
    Becker S; Simpson JC; Pepperkok R; Heinz S; Herder C; Grez M; Seifried E; Tonn T
    Thromb Haemost; 2004 Jul; 92(1):23-35. PubMed ID: 15213841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
    Neufeld EJ; Sidonio RF; O'Day K; Runken MC; Meyer K; Spears J
    J Med Econ; 2018 Aug; 21(8):762-769. PubMed ID: 29681200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional factor VIII made with von Willebrand factor at high levels in transgenic milk.
    Pipe SW; Miao H; Butler SP; Calcaterra J; Velander WH
    J Thromb Haemost; 2011 Nov; 9(11):2235-42. PubMed ID: 21920013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced Proteolytic Processing of Recombinant Human Coagulation Factor VIII B-Domain Variants by Recombinant Furins.
    Demasi MA; de S Molina E; Bowman-Colin C; Lojudice FH; Muras A; Sogayar MC
    Mol Biotechnol; 2016 Jun; 58(6):404-14. PubMed ID: 27126696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
    Delignat S; Dasgupta S; André S; Navarrete AM; Kaveri SV; Bayry J; André MH; Chtourou S; Tellier Z; Lacroix-Desmazes S
    Haematologica; 2007 Oct; 92(10):1423-6. PubMed ID: 18024377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products.
    Jankowski W; Park Y; McGill J; Maraskovsky E; Hofmann M; Diego VP; Luu BW; Howard TE; Kellerman R; Key NS; Sauna ZE
    Blood Adv; 2019 May; 3(9):1429-1440. PubMed ID: 31053570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of recombinant factor VIII products in patients with hemophilia A.
    Musso R
    Drugs Today (Barc); 2008 Oct; 44(10):735-50. PubMed ID: 19137127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice.
    Qadura M; Waters B; Burnett E; Chegeni R; Bradshaw S; Hough C; Othman M; Lillicrap D
    Blood; 2009 Jul; 114(4):871-80. PubMed ID: 19411636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative glycosylation mapping of plasma-derived and recombinant human factor VIII.
    Qu J; Ma C; Xu XQ; Xiao M; Zhang J; Li D; Liu D; Konkle BA; Miao CH; Li L; Xiao W
    PLoS One; 2020; 15(5):e0233576. PubMed ID: 32442215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
    Rea C; Dunkerley A; Sørensen B; Rangarajan S
    Haemophilia; 2009 Nov; 15(6):1237-42. PubMed ID: 19664015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioengineering of coagulation factor VIII for improved secretion.
    Miao HZ; Sirachainan N; Palmer L; Kucab P; Cunningham MA; Kaufman RJ; Pipe SW
    Blood; 2004 May; 103(9):3412-9. PubMed ID: 14726380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Factor VIII assays in treated hemophilia A patients].
    Lasne D; Pouplard C; Nougier C; Eschwege V; Le Cam Duchez V; Proulle V; Smahi M; Harzallah I; Voisin S; Toulon P; Sobas F; Galinat H; Flaujac C; Ternisien C; Jeanpierre E;
    Ann Biol Clin (Paris); 2019 Feb; 77(1):53-65. PubMed ID: 30799298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.